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Original Article
Lasmiditan for the acute treatment
of migraine: Subgroup analyses
by prior response to triptans
Kerry Knievel1, Andrew S Buchanan2, Louise Lombard2,
Simin Baygani2, Joel Raskin2, John H Krege2, Li Shen Loo2,
Mika Komori2 and Joshua Tobin3
Abstract
Background: Lasmiditan demonstrated superiority to placebo in the acute treatment of migraine in adults with mod-
erate/severe migraine disability in two similarly designed Phase 3 trials, SAMURAI and SPARTAN. Post-hoc integrated
analyses evaluated the efficacy of lasmiditan in patients who reported a good or insufficient response to triptans and in
those who were triptan naı̈ve.
Methods: Subgroups of patients reporting an overall response of ‘‘good’’ or ‘‘poor/none’’ to the most recent use of a
triptan at baseline (defined as good or insufficient responders, respectively) and a triptan-naı̈ve subpopulation were
derived from combined study participants randomized to receive lasmiditan 50 mg (SPARTAN only), 100 mg or 200 mg,
or placebo, as the first dose. Outcomes including headache pain-freedom, most bothersome symptom-freedom, and
headache pain relief 2 hours post-first dose of lasmiditan were compared with placebo. Treatment-by-subgroup analyses
additionally investigated whether therapeutic benefit varied according to prior triptan response (good or insufficient).
Results: Regardless of triptan response, lasmiditan showed higher efficacy than placebo (most comparisons were
statistically significant). Treatment-by-subgroup analyses found that the benefit over placebo of lasmiditan did not vary
significantly between patients with a good response and those with an insufficient response to triptans. Lasmiditan also
showed higher efficacy than placebo in triptan-naı̈ve patients.
Conclusions: Lasmiditan demonstrated comparable efficacy in patients who reported a good or insufficient response to
prior triptan use. Lasmiditan also showed efficacy in those who were triptan naı̈ve. Lasmiditan may be a useful therapeutic
option for patients with migraine.
Trial Registration: SAMURAI (NCT02439320); SPARTAN (NCT02605174).
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Date received: 16 July 2019; revised: 4 October 2019; accepted: 22 October 2019
Introduction
In 2016, the World Health Organization Global Burden
of Disease (GBD) study listed migraine as the second
leading cause of years lived with disability worldwide,
after low back pain (1). Despite the availability of mul-
tiple pharmacological options for treating migraine
attacks, unmet medical needs remain high, with
40% of people with episodic migraine reporting 1
unmet need with their current acute treatment in a
population-based study (2). Of those with unmet
needs, 37% were dissatisfied with their current migraine
acute treatment (citing adverse events, lack of efficacy,
or overall dissatisfaction with the medication as rea-
sons) (2). Furthermore, people with 1 unmet need
were more likely than those with no unmet needs to
have used triptans in the past 3 months (2).
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The principal safety concern with triptans, the stan-
dard acute treatment for migraine, relates to rare
reports of serious vascular adverse reactions due to
vasoconstriction (3). Consequently, these drugs are
contraindicated in people with certain cardiovascular/
cerebrovascular conditions, such as myocardial infarc-
tion, peripheral vascular disease, ischemic heart disease,
stroke, transient ischemic attack, and uncontrolled
hypertension (4,5). Additionally, 30–40% of people
with migraine have insufficient efficacy or tolerability
to triptans (6–10) or are unwilling to take triptans for
reasons that include a fear of adverse events (11).
Hence, there is a significant unmet need for novel
migraine therapies with a mechanism of action distinct
from that of triptans.
Lasmiditan is a highly selective 5-hydroxytryptamine
(5-HT)1F receptor agonist with central nervous system
penetration. This molecule is among the first of a new
class of treatments, termed ditans, investigated for the
acute treatment of migraine (12). The chemical struc-
ture of lasmiditan differs from that of triptans in that it
does not contain the indole core characteristic of trip-
tans, but instead exhibits a pyridinoyl-piperidine scaf-
fold not found in any other class of antimigraine agents
(13). Lasmiditan is also thought to differ from triptans
in its pharmacological effects. Triptans are potent
5-HT1B/1D receptor agonists and are thought to exert
vasoconstrictive effects via the activation of 5-HT1B
receptors in addition to having effects at the sensory
nerves of the trigeminal system (12). In contrast, there
is evidence that the pharmacological effects of lasmidi-
tan do not include a vascular mechanism, but instead
involve selective activation of 5HT1F receptors.
Although lasmiditan crosses the blood–brain barrier
and 5-HT1F receptors are located on trigeminal nerve
terminals and other areas of the brain, the specific site
of action has not been definitively elucidated (12,14–
17). Lasmiditan did not vasoconstrict ex-vivo rabbit
saphenous veins, ex-vivo human middle meningeal,
coronary, or internal mammary arteries, or in-vivo
dog coronary or carotid arteries (12,18,19).
Lasmiditan has demonstrated superiority to placebo
in the acute treatment of migraine in two similarly
designed Phase 3, prospective, randomized, double-
blind, placebo-controlled, single migraine attack trials,
SAMURAI and SPARTAN (20,21). In both studies,
the percentage of patients who were migraine
pain-free 2 hours post-dose was significantly greater
with all doses of lasmiditan than with placebo (primary
endpoint) (20,21).
Given that lasmiditan and triptans exhibit structural
and pharmacological differences, this post-hoc inte-
grated analysis of data from the SAMURAI and
SPARTAN studies was conducted to investigate the
response to lasmiditan for the acute treatment of
migraine in patients who reported a good or insufficient
response to prior triptan use, and in those who were
triptan naı̈ve.
Methods
SAMURAI and SPARTAN were similarly designed
studies (see the Supplemental Material) (20,21). Brief
descriptions of the patient populations and designs of
the two studies are given below; full details have been
published (20,21).
Study populations
SAMURAI (NCT02439320) and SPARTAN
(NCT02605174) were conducted in adults diagnosed
with migraine with or without aura (International
Classification of Headache Disorders 2nd edition, sub-
types 1.1 and 1.2.1) (22); a history of 3–8 migraine
attacks (<15 headache days) per month and moderate/
severe migraine disability (Migraine Disability
Assessment [MIDAS] score 11). SAMURAI, but
not SPARTAN, excluded patients with known coron-
ary artery disease, clinically significant arrhythmia,
or uncontrolled hypertension. Inclusion and exclusion
criteria common to both studies are provided in the
Supplemental Material.
Study designs
Participants were randomized evenly to receive lasmi-
ditan 50mg (SPARTAN only), 100mg, 200mg, or pla-
cebo. Randomization was stratified for the use of
migraine preventives. Information on medication his-
tory and concomitant medications was collected at
baseline. For each previous migraine medication,
patients were asked to rate whether their overall
response to treatment had been ‘‘good,’’ ‘‘poor,’’ or
‘‘none.’’ Participants were asked to treat their next
migraine attack within 4 hours of pain onset provided
that the headache was of at least moderate severity and
not improving. Participants were instructed to record
pain, associated symptoms, and interference with
normal activities at the start of a migraine attack and
at prespecified intervals (0.5, 1, 1.5, 2, 3, 4, 24, and 48
hours) post-dose using an electronic diary (eDiary).
At each time point, patients recorded the following:
Severity of pain using the International Headache
Society (IHS) 4-point pain severity rating scale
(none, mild, moderate, or severe); presence/absence of
self-identified most bothersome migraine-associated
symptom (e.g. nausea, phonophobia, or photophobia);
and level of migraine-associated disability (degree
of interference with normal activities) using a
4-point scale (‘‘not at all,’’ ‘‘mild interference,’’
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‘‘marked interference,’’ and ‘‘need complete bed rest’’).
Two hours post-dose, patients completed the Patient
Global Impression of Change (PGIC) choosing from
one of seven responses, ranging from ‘‘very much
better’’ to ‘‘very much worse.’’
The eDiary was also used daily to record how
patients were feeling (possible answers: ‘‘fine/normal’’
or ‘‘not well’’) and if they felt ‘‘anything unusual’’ since
taking the study medication not experienced previously
with a migraine attack (possible answers: ‘‘yes’’ or
‘‘no’’). ‘‘Not well’’ or ‘‘yes’’ answers to these questions
prompted investigation by the site to determine if an
adverse event (AE) had occurred.
Outcomes investigated
The primary efficacy endpoint for both studies was the
difference between lasmiditan and placebo in the pro-
portion of patients who were headache pain-free at 2
hours post-dose (defined as a reduction in pain severity
from mild, moderate, or severe at baseline to no pain).
This outcome was assessed in the modified intent-to-
treat (mITT) population, defined as all randomized
participants who used at least one dose of the study
drug and underwent any post-dose headache severity
or symptom assessments (intent-to-treat [ITT] group)
and who treated a migraine attack within 4 hours of
pain onset. The key secondary efficacy endpoint was
the comparison between lasmiditan and placebo in
the proportion of patients who were most bothersome
symptom (MBS)-free at 2 hours post-dose (mITT
population).
Other secondary efficacy endpoints assessed 2 hours
post-first dose in the ITT population were: headache
pain relief, a migraine-related disability score of ‘‘not
at all,’’ and a PGIC rating of ‘‘very much better’’
or ‘‘much better.’’ Disability shift from baseline was
also assessed.
Proportions of patients with any treatment-emergent
AE (safety population, defined as all randomized
participants who used at least one dose of the study
drug, regardless of whether or not they underwent
any post-dose study assessments) were investigated. A
treatment-emergent AE was defined as an event that
started or worsened after the first dose of study medi-
cation and occurred within 48 hours of the last dose (a
duration well over five times the half-life of lasmiditan
(data on file, Eli Lilly and Company).
The main subpopulations studied (based on patient-
reported prior use of triptans at baseline) were:
. Triptan experienced: Patients who had at least one
triptan recorded as a current or prior migraine treat-
ment, regardless of time elapsed since last triptan.
Subgroups of patients reporting an overall response
of ‘‘good’’ or ‘‘poor/none’’ to the most recent use of
a triptan at baseline were defined as good or insuffi-
cient responders, respectively.
. Triptan naı̈ve: Patients who did not have a triptan
recorded as a current or prior migraine treatment.
The results of analyses conducted in triptan-experi-
enced (good or insufficient responders) and triptan-
naı̈ve subpopulations, and for the outcomes headache
pain-freedom (primary efficacy endpoint), MBS-free-
dom, and headache pain relief at 2 hours post-dose are
reported here. Results of analyses conducted in add-
itional triptan user subpopulations and for the other
secondary outcomes (all subpopulations) are presented
in the Supplemental Material.
For all subpopulations, response to lasmiditan was
assessed versus placebo.
Statistical analyses
These post-hoc analyses evaluated combined
SAMURAI and SPARTAN data. For each subpopu-
lation, outcomes were compared between treatment
groups using a two-sided test from a logistic regression
model with study, treatment group, and background
use of medication to reduce the frequency of migraine
attacks as covariates. Comparisons versus placebo were
considered statistically significant at the p< 0.05 level.
For comparisons between the triptan good responder
and insufficient responder subgroups, Mantel–Haenszel
odds ratios, 95% confidence intervals, and general
association p-values at each measured time point, stra-
tified by study, are displayed.
Patients with missing data for any outcome at any
particular time point were assumed not to have
achieved that outcome at that time point.
Additional treatment-by-subgroup analyses of out-
comes were carried out to determine whether therapeutic
benefit varied according to prior triptan response versus
placebo. For each outcome, the p-value for treatment-
by-subgroup interaction was based on a logistic regres-
sion model with treatment-by-subgroup interaction term
and study, treatment group, and subgroup as covariates.
Significance for interaction was defined as p< 0.1.
Results
A total of 3981 patients were included in these analyses;
patient demographics and disease characteristics for
the triptan-experienced and -naı̈ve subpopulations are
described in Table 1.
Of the combined SAMURAI and SPARTAN
populations, 45% overall had used at least one triptan
(triptan-experienced subpopulation) previously at
some point.
Knievel et al. 21
Efficacy response to lasmiditan versus placebo
in patients with good or insufficient response
to triptans
Patients who described themselves as insufficient
responders to their last triptan comprised 31% of the
triptan-experienced subpopulation.
In subgroup analyses, lasmiditan showed efficacy in
both triptan good responders and triptan insufficient
responders for the outcomes of headache pain-freedom,
MBS-freedom, and headache pain relief, with all com-
parisons being statistically significant versus placebo
for the 100mg and 200mg doses (Figure 1).
Treatment-by-subgroup analyses found that the
benefit over placebo of lasmiditan 50mg, 100mg, or
200mg did not vary significantly between prior triptan
good and insufficient responders based on the same
three efficacy measures at 2 hours post-first dose
(Figure 2).
Efficacy response to lasmiditan versus placebo
in triptan-naı̈ve patients
Lasmiditan demonstrated efficacy in the triptan-naı̈ve
subpopulation, with all responses to lasmiditan 100mg
and 200mg across all outcomes (headache pain-
freedom, MBS-freedom, and headache pain relief)
being significantly higher (p< 0.05) than with placebo
(Figure 3).
Adverse events
Across subpopulations, treatment-emergent AE pro-
files in patients receiving lasmiditan were generally
similar regardless of prior experience with, or response
to, triptan use (data not shown).
Discussion
In this integrated analysis of two similarly designed
Phase 3, prospective, randomized, double-blind, pla-
cebo-controlled trials (SAMURAI and SPARTAN),
response to lasmiditan for the acute treatment of
migraine was found to be effective versus placebo in
both good and insufficient responders to prior triptans,
and in patients who were triptan naı̈ve.
About 45% of the combined SAMURAI and
SPARTAN study populations had previously used a
triptan. As would be expected, prior triptan use was
higher in SAMURAI and SPARTAN (both studies
were conducted in patients with moderate-to-severe
migraine disability [MIDAS score 11]) (20,21) than
in longitudinal and cross-sectional population-based
and real-world studies (18–37%) (23–26).
Evidence from controlled trials and observa-
tional studies suggests that 30–40% of people
with migraine have insufficient efficacy or tolerability
to triptan therapy (6–9), a finding reflected in the results
of this combined analysis: 31% of patients in the trip-
tan-experienced subpopulation reported an insufficient
response to prior triptans. Patients may consider them-
selves insufficient responders to triptans for a variety of
reasons, including a lack of efficacy and intolerable
adverse events (2,27).
In this integrated analysis, lasmiditan demonstrated
higher efficacy versus placebo for all outcomes in
patients who reported an insufficient response to prior
triptan therapy. Additionally, response to lasmiditan
versus placebo in patients who self-reported an insuffi-
cient response to prior triptan use was similar to that in
those who reported a good response to triptans, again
across all outcomes.
Unmet needs with acute therapy for migraine remain
high, with some patients unable to achieve optimal out-
comes with current therapies (2,28). Lasmiditan might
offer an effective acute treatment option for these
patients and would expand the therapeutic choices
available both for people with migraine and their treat-
ing physicians.
Triptan-naı̈ve patients may have contraindica-
tions to triptans (e.g. cardiovascular/cerebrovascular
conditions) (4,5). Additionally, such patients may
be unwilling to take a triptan, or physicians may
be reluctant to prescribe a triptan, for reasons
that include a fear of AEs (11,29). Responses to lasmi-
ditan were generally superior to placebo for head-
ache pain-freedom, MBS-freedom, and headache
pain relief 2 hours post-first dose in the triptan-naı̈ve
subpopulation in this integrated analysis. These find-
ings suggest a possible role for lasmiditan as an
option for the acute treatment of migraine in triptan-
naı̈ve patients.
Table 1. Baseline patient demographics and disease character-






Age, years 44.1 (11.9) 40.6 (12.6)
Female, n (%) 1581 (88.5) 1774 (80.8)
Years since migraine
diagnosis
21.5 (13.3) 16.4 (12.0)
Migraine attacks/month** 5.3 (1.9) 5.2 (1.9)
*Includes patients with a good or insufficient response to prior triptan
use.
**Based on response to the question in migraine history section of the
case report form: ‘‘Frequency of migraine attacks (average) during the last
three months.’’
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Figure 1. Subgroup analyses by response to prior triptan therapy (good or insufficient) for (a) headache pain freedom, (b) MBS
freedom, and (c) headache pain relief 2 hours post-first dose with lasmiditan 50 mg, 100 mg, and 200 mg versus placebo.
**p< 0.01 vs. placebo.
***p< 0.001 vs. placebo.
yAssessed in the modified intention-to-treat (ITT) population.
yyAssessed in the ITT population.
MBS, most bothersome symptom.
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The efficacy and tolerability of lasmiditan in patients
with cardiovascular contraindications to triptans is
of interest. Known coronary artery disease, clinically
significant arrhythmia, or uncontrolled hypertension
were exclusion criteria for the SAMURAI, but not
the SPARTAN, study. However, the limited number
of patients with pre-existing cardiovascular conditions
included in this integrated analysis of the two studies
precluded meaningful investigations into outcomes
with lasmiditan in this patient subpopulation.
When conducting multiple subgroup analyses, there
is a substantial probability of false-positive findings
(30). A strength of this study is that any multiplicity
issues arising from treatment-by-subgroup analyses
were addressed by comparing the actual number of sig-
nificant findings with those expected by chance alone
(30). The results reported here are supported by the
additional analyses provided in the Supplemental
Material. Based on a total of 35 independent tests for
interaction at the 0.1 significance level conducted in
total, the number found to be significant (2; both in
the additional analyses reported in the Supplemental
Material) was in line with that expected (3), suggesting
that there was no heterogeneity in the response of
any subgroup versus its complementary subgroup.
Limitations include that neither SAMURAI nor
SPARTAN had an active triptan comparator; hence,
it was not possible to compare the efficacy of lasmiditan
directly with that of a triptan in patients with an inade-
quate prior response to triptans. Additionally, analyses
were post-hoc and low patient numbers in some sub-
populations limited the conclusions that could be
drawn. Results for the 50mg dose of lasmiditan were
based solely on data from the SPARTAN study.
Although patient responses to this dose were all numer-












































































































Figure 2. Treatment-by-subgroup analyses by response to prior triptan therapy (good or insufficient) for headache pain freedom,
MBS freedom, and headache pain relief 2 hours post-first dose with lasmiditan 50 mg, 100 mg, and 200 mg versus placebo.
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Figure 3. Proportions of patients (a) headache pain-free, (b) MBS-free, and (c) with headache pain relief at 2 hours post-first dose
with lasmiditan 50 mg, 100 mg, and 200 mg versus placebo in the triptan-naı̈ve subpopulation.
*p< 0.05 vs. placebo.
***p< 0.001 vs. placebo.
yAssessed in the modified intention-to-treat (ITT) population.
yyAssessed in the ITT population.
CI: confidence interval; MBS: most bothersome symptom; OR: odds ratio.
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subpopulations and outcomes assessed, in some
instances there was not enough evidence to declare stat-
istical significance. In both the SAMURAI and
SPARTAN studies, response to previous triptan ther-
apy (good or insufficient) was a subjective assessment
by the patient, and reasons for each patient’s assess-
ment were not explored (20,21).
Details, such as the timing of triptan dosing relative
to migraine onset (current recommendations are to treat
early) (31), and information on dosing (including up
titration) or route of administration, were not collected.
Conclusion
Lasmiditan demonstrated efficacy in both patients with
a good response and those with an insufficient response
to prior triptan therapy, as well as in those who were
triptan naı̈ve.
Clinical implications
. Lasmiditan demonstrated efficacy in patients who reported a good or insufficient response to prior triptan
therapy, as well as in those who were triptan naı̈ve.
. Lasmiditan efficacy was also generally similar between those who reported a good response and those who
reported an insufficient response to prior triptan therapy.
. Lasmiditan may be a useful treatment option for the acute treatment of migraine regardless of prior triptan
response and for patients naı̈ve to triptans.
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